[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-flow-nasal-oxygen-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-flow-nasal-oxygen-therapy":55},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100524148","weaning-protocol-for-high-flow-nasal-oxygen-therapy-in-intensive-care-100524148",false,"NCT06104956","Weaning Protocol for High-flow Nasal Oxygen Therapy in Intensive Care","Weaning Protocol for High-flow Nasal Oxygen Therapy in Intensive Care: A Multicentre Randomised Controlled Trial","HiFloWEAN","Inclusion Criteria:\n\n* Major patient admitted to the intensive care unit or continuous care unit for de novo hypoxaemic acute respiratory failure (with a PaO2\u002FFiO2 ratio \\\u003C300 mmHg)\n* Treated with HDNO for at least 24 hours in an intensive care unit or continuous care unit\n* Treated with HFNO with a flow rate ≥ 50L\u002Fmin and inspired oxygen fraction (FiO2) ≥ 0.5, at inclusion\n* With a ROX index (SpO2\u002FFiO2\u002FRespiratory Rate) stable or improving in the 6 hours prior to inclusion and greater than 4.88 (the patient must not be in a worsening phase).\n* Had a blood gas test under HFNO within 24 hours of inclusion\n* Participant covered by or entitled to social security\n* Informed consent signed by the patient or its relatives if the patient is incapable; this consent must then be confirmed by the patient as soon as possible\n\nExclusion Criteria:\n\n* Presence of a patient included in the study and not weaned off HFNO in the sector managed by the nurse of the patient assessed for eligibility\n* Concomitant non-invasive ventilation treatment\n* Use of HFNO within 7 days of extubation\n* Chronic obstructive pulmonary disease (Gold grade 3 or 4)\n* Cardiogenic acute pulmonary oedema as the main cause of acute respiratory failure\n* Diffuse interstitial lung disease as a medical history\n* Patient with long-term non-invasive ventilation with external positive pressure\n* Patient on long-term oxygen therapy at home\n* Pregnant women, women in labour and breastfeeding mothers\n* Persons deprived of their liberty by a judicial or administrative decision, persons hospitalised without consent and persons admitted to a health or social establishment for purposes other than research.\n* Minor\n* Adult subject to a legal protection measure (guardianship, curators, person under court protection)\n* Patient with a medical decision not to intubate\n* Patients already included in the study, neither for the same stay if they were to present the inclusion criteria again, nor for subsequent stays","ALL","18 Years","90 Years",{"count":21,"type":22},370,"ESTIMATED","INTERVENTIONAL",[25],"NA","High-flow nasal oxygen therapy (HFNO) is an oxygenation technique frequently used in intensive care.\n\nThe main objective of our study is to show that the use of a protocol for weaning patients off high-flow nasal oxygen therapy (HFNO) in the intensive care unit increases the probability that patients will be weaned from HFNO at Day 7 post-randomisation.\n\nThis is a open-label multicentre randomised controlled trial conducted in two parallel groups.\n\nThe primary endpoint is the success rate at Day 7, with success defined as \"definitive\" weaning from HFNO, i.e. patients weaned from HFNO for more than 48 hours without recourse to non-invasive ventilation (NIV) or intubation and still alive at Day 7.\n\nThe weaning protocol will be started as soon as the patient meets all the inclusion criteria, considered to be the prerequisites for initiating weaning from HFNO. Patients will be monitored until Day 28 maximum.",[28,29],"Acute Hypoxemic Respiratory Failure","High-flow Nasal Oxygen Therapy","RECRUITING","2025-07-25",{"date":33,"type":34},"2025-07-30","ACTUAL",{"date":36,"type":34},"2024-02-17",{"date":38,"type":22},"2027-03",{"name":40,"class":41},"University Hospital, Tours","OTHER",11,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100577259","effects-of-face-mask-continuous-positive-airway-pressure-vs-noninvasive-ventilation-vs-high-flow-nasal-oxygen-on-intubation-free-survival-in-acute-hypoxemic-respiratory-failure-the-tripod-randomized-clinical-trial-100577259","NCT06795971","Effects of Face Mask Continuous Positive Airway Pressure Vs. Noninvasive Ventilation Vs. High-flow Nasal Oxygen on Intubation-free Survival in Acute Hypoxemic Respiratory Failure: the TRIPOD Randomized Clinical Trial","TRIPOD","Inclusion Criteria:\n\n1. Age≥18 yrs;\n2. A ratio of the partial pressure of arterial oxygen (PaO2) to the FiO2 of 300 mm Hg or less, or a ratio of pulse oximetry oxygen saturation (SpO2) to the FiO2 of 315 or less (SpO2≤97%) and the need for (1) noninvasive positive pressure ventilation with at least 5 cm H2O PEEP, or (2) high-flow nasal cannula at 30L\u002Fmin or higher, or (3) standard oxygen with oxygen flow rate of at least 10 L\u002Fmin;\n3. Sign informed consent.\n\nExclusion Criteria:\n\n1. Patients that have already received Continuous positive airway pressure, Noninvasive ventilation continuously for more than 24 hours before the screening visit.\n2. Previous bout of mechanical ventilation during index hospitalization.\n3. Exacerbation of chronic lung disease, including asthma or chronic obstructive pulmonary disease.\n4. Moderate to severe cardiac insufficiency (New York Heart Association class \\>II or left ventricular ejection fraction\\\u003C50%) or cardiogenic pulmonary edema.\n5. Hemodynamic dysfunction, defined as vasopressor dose \\> 0.3 µg\u002Fkg\u002Fmin of norepinephrine-equivalent to maintain systolic blood pressure \\> 90 mm Hg.\n6. Impaired consciousness with a Glasgow coma score ≤ 12.\n7. Patients with urgent need for intubation, including respiratory or cardiac arrest, respiratory pauses with loss of consciousness or gasping for air, severe hypoxemia defined as SpO2 lower than 90% despite maximal oxygen support.\n8. Patients with contraindication to NIV according to the French consensus conference, patient refusal, cardiorespiratory arrest, coma, non-drained pneumothorax, unresolved vomiting, upper airway obstruction, hematemesis or severe facial trauma, thoracic or abdominal surgery in the previous 7 days.\n9. A do-not-intubate order at time of inclusion.\n10. Pregnancy.",{"count":51,"type":22},1300,[25],"Acute hypoxemic respiratory failure (AHRF) is a common indication for admission to an intensive care unit (ICU), with mortality exceeding 50% in cases where invasive mechanical ventilation is needed. Therefore, assessment of the most adequate oxygen strategy to avoid intubation in patients with AHRF deserves consideration.Previous studies have indicated that non-invasive oxygenation strategies, including high-flow nasal oxygen (HFNO), helmet or face mask noninvasive ventilation (NIV), and continuous positive airway pressure (CPAP), are effective in preventing endotracheal intubation in adult patients with AHRF when compared to the standard oxygen therapy. However, the optimal non-invasive oxygenation strategies remain uncertain. This study aim to determine whether CPAP, compared with HFNC or NIV, increase the intubation-free survival during study period in patients with AHRF.",[28,55,56,57],"High-Flow Nasal Oxygen Therapy","Noninvasive Ventilation","Continuous Positive Airway Pressure (CPAP)","2025-02-24",{"date":60,"type":34},"2025-02-26",{"date":62,"type":34},"2025-01-23",{"date":64,"type":22},"2027-12-31",{"name":66,"class":41},"Southeast University, China",1]